{"filing":{"accession_number":"0001193125-26-374328","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-25","primary_document":"d116527d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm"},"events":[{"id":30297,"run_id":27771,"accession_number":"0001193125-26-374328","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware (case number 26-10989), representing a terminal event materially threatening the registrant's continued existence.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32857,"accession_number":"0001193125-26-374328","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware (case number 26-10989). The filing is disclosed under Item 1.03 (Bankruptcy or Receivership) and represents a terminal event materially threatening the registrant's continued existence. While the disclosure also describes a subsequent asset sale to PTC Therapeutics, the primary event disclosed in this Item 1.03 section is the bankruptcy filing itself, which is the most material and existential event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:27.369586+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30298,"run_id":27771,"accession_number":"0001193125-26-374328","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Sangamo Therapeutics entered into a material definitive asset purchase agreement with PTC Therapeutics for the sale of certain assets, disclosed in connection with the Chapter 11 bankruptcy filing.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32856,"accession_number":"0001193125-26-374328","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into a material definitive agreement related to a PTC Asset Purchase Agreement. The reference to Item 1.03 (which typically covers bankruptcy and receivership but here appears to reference an asset purchase) indicates this is a material acquisition or disposition of assets. Asset purchase agreements are core M\u0026A activity and are material to investors assessing the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:27.369586+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32856,"accession_number":"0001193125-26-374328","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into a material definitive agreement related to a PTC Asset Purchase Agreement. The reference to Item 1.03 (which typically covers bankruptcy and receivership but here appears to reference an asset purchase) indicates this is a material acquisition or disposition of assets. Asset purchase agreements are core M\u0026A activity and are material to investors assessing the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:27.369586+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-28"},{"id":32857,"accession_number":"0001193125-26-374328","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware (case number 26-10989). The filing is disclosed under Item 1.03 (Bankruptcy or Receivership) and represents a terminal event materially threatening the registrant's continued existence. While the disclosure also describes a subsequent asset sale to PTC Therapeutics, the primary event disclosed in this Item 1.03 section is the bankruptcy filing itself, which is the most material and existential event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:27.369586+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-08-28"}]}